GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Buy ALKS
up 316.68 %

Alkermes, Inc. (ALKS) rated Buy

Posted on: Tuesday,  Dec 18, 2007  9:25 AM ET by Banc of America Sec

Banc of America Sec rated Buy Alkermes, Inc. (NASDAQ: ALKS) on 12/18/2007, when the stock price was $14.68.
Since then, Alkermes, Inc. has gained 316.69% as of 01/21/2016's recent price of $61.17.
If you would have followed this Banc of America Sec's recommendation on ALKS, you would have gained 316.68% of your investment in 2956 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Integrity, objectivity and originality are cornerstones of the value–added research that we offer to corporate and institutional clients. As thought leaders, our goal is to help clients understand and adapt to changing economic conditions and events that drive markets, currencies, industries and companies worldwide. And we deliver innovative ideas based on rigorous primary research, sound principles and clear vision. Our research teams are organized by areas of expertise, from equities, fixed income and emerging markets to foreign exchange and global financial risk advisory – featuring many of the industry’s most respected analysts and economists. Through our private, password–protected Web portal, our clients have access to a comprehensive array of timely research and commentary, including: * U.S. and global economic updates and indicators * Federal budget and fiscal policy * Industry outlooks * Stock coverage and picks * Financial market strategies * Corporate bond issuer risk analysis
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/18/2007 9:25 AM Buy
None
14.68 18.00
as of 8/27/2015
1 Week down  -8.98 %
1 Month down  -8.68 %
3 Months up  1.95 %
1 YTD up  50.44 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy